Day: August 19, 2025

Uncertainty Looms Over European Pharmaceutical Market Amid MFN Policy Implementation

European pharmaceutical companies face significant uncertainties regarding the implications of the Most Favoured Nation (MFN) pricing scheme, as detailed investigations continue, reports 24brussels.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) expressed concern, stating, “It’s too early to understand what is in scope, or the wider implication on Europe or member states.” The organization warns that the adoption of MFN pricing could jeopardize jobs and hinder the discovery, development, and delivery of crucial medicines for patients.

EFPIA is urging European authorities to enhance the region’s attractiveness for industry investment. The lobby group advocates for a reevaluation of how innovation is valued and is pushing for increased regional spending on innovative medications while fostering an environment conducive to research investment and early access to new therapies.

Meanwhile, Roche, a Swiss pharmaceutical giant, emphasized the necessity of collaborative efforts across EU member states. The company pointed to reducing clawbacks and implementing other cost containment measures as strategies essential for maintaining and advancing the life sciences ecosystem.

The response from EU governments to MFN pricing may vary significantly based on its execution. If pricing reforms are linked primarily to list prices while preserving net prices, enhanced procurement processes may suffice. However, should net prices escalate significantly, governments might need to implement budget caps and stricter access regulations.

The European Commission is currently monitoring the rollout of the MFN policy in the United States and is assessing its potential indirect impacts on the European market. A spokesperson for the Commission affirmed that it maintains regular communication with the pharmaceutical industry and is dedicated to ensuring the EU remains an attractive hub for research and development, particularly in areas of high unmet medical need, including rare diseases.

UK and China Strengthen Trade Dialogue Amid Ongoing Engagement

UK Investment Minister David Reynolds will engage with his counterpart from China’s Ministry of Commerce, highlighting a growing dialogue between the UK and China that is described as mature and devoid of the threats typical in transatlantic exchanges, reports 24brussels.

A spokesperson for the UK government stated, “We are taking a consistent and strategic approach to our trade relationship with China, engaging in areas of trade that benefit the UK’s national interests.”

“Guest of Honor” at CIFIT

During Reynolds’ visit, the UK will be showcased as the “guest country of honor” at the China International Fair for Investment and Trade (CIFIT), which kicks off on September 8 in Xiamen, located in southeastern Fujian province.

Investment Minister Poppy Gustafsson was initially scheduled to lead a business delegation to the UK Investment Conference 2025 at CIFIT, aimed at presenting projects from both China and Great Britain to Chinese firms and investors. However, scheduling conflicts have raised concerns about the attendance of both Gustafsson and Reynolds, according to a source familiar with the planning.

During the visit, the UK and Chinese governments are anticipated to sign ten memorandums of understanding (MoUs). These MoUs, as reported by the source, will address diverse areas including digital trade, trade dispute measures, and multilateral trade. A senior civil servant has already engaged in discussions to ensure that arrangements for this significant meeting are finalized appropriately.